KYMRIAH®, a second-generation CAR T-cell product (4-1BB costimulatory domain) directed against CD19, is indicated for both paediatric and adult ALL patients and will be one of the focuses of this study. Here, CD19 is linked to acute lymphoblastic leukemia.